Skip to main content
. 2020 Aug 25;18:579–586. doi: 10.1016/j.omto.2020.08.012

Figure 2.

Figure 2

ASCs Induce Chemoresistance in Breast Carcinoma

(A) Flow cytometry on cisplatin-treated cells from MMTV-PyMT; Fsp1-cre; Rosa26-RFP-GFP mice demonstrates preferential survival of GFP+ cells compared to untreated controls (Figure 1C). (B) Flow cytometry data from (A) quantified for GFP+RFP+ cells. (C) Quantification of GFP+ MCF7 and SUM149 cells, cultured with or without (Control) human ASC, that survived cisplatin or paclitaxel treatment; normalized to no treatment (Control). Shown are mean ± SEM of N = 10 view fields. D-E, GFP+ SUM149 and MCF7 cells cultured with or without (Control) human mammary ASC were treated with cisplatin or paclitaxel. (D) Dying cells identified based on propidium iodide (PI) staining. (E) Quantified PI+ cells normalized to no treatment controls (−). For all data, shown are mean ± SEM of N = 10 view fields. ∗p < 0.05, unpaired Student’s t test. Scale bars, 50 μm.